Top

Published in:

Open Access 13-07-2023 | Pneumococcus | Original Research

Highly Resistant Serotype 19A Streptococcus pneumoniae of the GPSC1/CC320 Clone from Invasive Infections in Poland Prior to Antipneumococcal Vaccination of Children

Authors: Weronika Puzia, Jan Gawor, Robert Gromadka, Karolina Żuchniewicz, Izabela Wróbel-Pawelczyk, Patrycja Ronkiewicz, Agnieszka Gołębiewska, Waleria Hryniewicz, Ewa Sadowy, Anna Skoczyńska

Published in: Infectious Diseases and Therapy | Issue 8/2023

Abstract

Introduction

The introduction of pneumococcal conjugate vaccines (PCV) into the national immunization programs (NIPs) has significantly reduced the number of pneumococcal infections. However, infections caused by isolates of non-vaccine serotypes (NVT) started spreading shortly thereafter and strains of NVT 19A have become the main cause of invasive pneumococcal disease burden worldwide. The aim of the study was to characterize serotype 19A invasive pneumococci of GPSC1/CC320 circulating in Poland before the introduction of PCV into the Polish NIP in 2017 and to compare them to isolates from other countries where PCVs were implemented much earlier than in Poland.

Methods

All the GPSC1/CC320 isolates were analyzed by serotyping, susceptibility testing, and whole genome sequencing followed by analyses of resistome, virulome, and core genome multilocus sequence typing (cgMLST), including comparative analysis with isolates with publicly accessible genomic sequences (PubMLST).

Results

During continuous surveillance the NRCBM collected 4237 invasive Streptococcus pneumoniae isolates between 1997 and 2016, including 200 isolates (4.7%) of serotype 19A. The most prevalent among 19A pneumococci were highly resistant representatives of Global Pneumococcal Sequence Cluster 1/Clonal Complex 320, GPSC1/CC320 (n = 97, 48.5%). Isolates of GPSC1/CC320 belonged to three sequence types (STs): ST320 (75.2%) ST4768 (23.7%), and ST15047 (1.0%), which all represented the 19A-III cps subtype and had complete loci for both PI-1 and PI-2 pili types. On the basis of the cgMLST analysis the majority of Polish GPSC1/CC320 isolates formed a group clearly distinct from pneumococci of this clone observed in other countries.

Conclusion

Before introduction of PCV in the Polish NIP we noticed an unexpected increase of serotype 19A in invasive pneumococcal infections, with the most common being representatives of highly drug-resistant GPSC1/CC320 clone, rarely identified in Europe both before and even after PCV introduction.

Available only for authorised users

Weiser JN, Ferreira DM, Paton JC. Streptococcus pneumoniae: transmission, colonization and invasion. Nat Rev Microbiol. 2018;16(6):355–67. https://doi.org/10.1038/s41579-018-0001-8.CrossRefPubMedPubMedCentral

Wyllie AL, Wijmenga-Monsuur AJ, van Houten MA, et al. Molecular surveillance of nasopharyngeal carriage of Streptococcus pneumoniae in children vaccinated with conjugated polysaccharide pneumococcal vaccines. Sci Rep. 2016;6:23809. https://doi.org/10.1038/srep23809.CrossRefPubMedPubMedCentral

WHO. Pneumococcal vaccines WHO position paper--2012. Wkly Epidemiol Rec. 2012;87(14):129–44, https://www.ncbi.nlm.nih.gov/pubmed/24340399. Accessed 16 May 2022.

Ganaie F, Saad JS, McGee L, et al. A new pneumococcal capsule type, 10D, is the 100th serotype and has a large cps fragment from an oral Streptococcus. mBio. 2020;11(3). https://doi.org/10.1128/mbio.00937-20.CrossRefPubMedPubMedCentral

Ruiz Garcia Y, Nieto Guevara J, Izurieta P, Vojtek I, Ortega-Barria E, Guzman-Holst A. Circulating clonal complexes and sequence types of Streptococcus pneumoniae serotype 19a worldwide: the importance of multidrug resistance: a systematic literature review. Expert Rev Vaccines. 2021;20(1):45–57. https://doi.org/10.1080/14760584.2021.1873136.CrossRefPubMed

Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003;348(18):1737–46. https://doi.org/10.1056/NEJMoa022823.CrossRefPubMed

Andrejko K, Ratnasiri B, Hausdorff WP, Laxminarayan R, Lewnard JA. Antimicrobial resistance in paediatric Streptococcus pneumoniae isolates amid global implementation of pneumococcal conjugate vaccines: a systematic review and meta-regression analysis. Lancet Microbe. 2021;2(9):e450–60. https://doi.org/10.1016/S2666-5247(21)00064-1.CrossRefPubMedPubMedCentral

Hicks LA, Harrison LH, Flannery B, et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998–2004. J Infect Dis. 2007;196(9):1346–54. https://doi.org/10.1086/521626.CrossRefPubMed

Brueggemann AB, Pai R, Crook DW, Beall B. Vaccine escape recombinants emerge after pneumococcal vaccination in the United States. PLoS Pathog. 2007;3(11):e168. https://doi.org/10.1371/journal.ppat.0030168.CrossRefPubMedPubMedCentral

10.

Cassiolato AP, Almeida SCG, Andrade AL, Minamisava R, Brandileone MCC. Expansion of the multidrug-resistant clonal complex 320 among invasive Streptococcus pneumoniae serotype 19A after the introduction of a ten-valent pneumococcal conjugate vaccine in Brazil. PLoS ONE. 2018;13(11):e0208211. https://doi.org/10.1371/journal.pone.0208211.CrossRefPubMedPubMedCentral

11.

Isturiz R, Sings HL, Hilton B, Arguedas A, Reinert RR, Jodar L. Streptococcus pneumoniae serotype 19A: worldwide epidemiology. Expert Rev Vaccines. 2017;16(10):1007–27. https://doi.org/10.1080/14760584.2017.1362339.CrossRefPubMed

12.

Reinert R, Jacobs MR, Kaplan SL. Pneumococcal disease caused by serotype 19A: review of the literature and implications for future vaccine development. Vaccine. 2010;28(26):4249–59. https://doi.org/10.1016/j.vaccine.2010.04.020.CrossRefPubMed

13.

Gladstone RA, Lo SW, Lees JA, et al. International genomic definition of pneumococcal lineages, to contextualise disease, antibiotic resistance and vaccine impact. EBioMedicine. 2019;43:338–46. https://doi.org/10.1016/j.ebiom.2019.04.021.CrossRefPubMedPubMedCentral

14.

Metcalf BJ, Gertz RE Jr, Gladstone RA, et al. Strain features and distributions in pneumococci from children with invasive disease before and after 13-valent conjugate vaccine implementation in the USA. Clin Microbiol Infect. 2016;22(1):60e9–e29. https://doi.org/10.1016/j.cmi.2015.08.027.CrossRef

15.

Schroeder MR, Chancey ST, Thomas S, et al. A population-based assessment of the impact of 7- and 13-valent pneumococcal conjugate vaccines on macrolide-resistant invasive pneumococcal disease: emergence and decline of Streptococcus pneumoniae serotype 19A (CC320) with dual macrolide resistance mechanisms. Clin Infect Dis. 2017;65(6):990–8. https://doi.org/10.1093/cid/cix446.CrossRefPubMedPubMedCentral

16.

Choi EH, Kim SH, Eun BW, et al. Streptococcus pneumoniae serotype 19A in children. South Korea Emerg Infect Dis. 2008;14(2):275–81. https://doi.org/10.3201/eid1402.070807.CrossRefPubMed

17.

Dagan R, Givon-Lavi N, Leibovitz E, Greenberg D, Porat N. Introduction and proliferation of multidrug-resistant Streptococcus pneumoniae serotype 19A clones that cause acute otitis media in an unvaccinated population. J Infect Dis. 2009;199(6):776–85. https://doi.org/10.1086/597044.CrossRefPubMed

18.

Shin J, Baek JY, Kim SH, Song JH, Ko KS. Predominance of ST320 among Streptococcus pneumoniae serotype 19A isolates from 10 Asian countries. J Antimicrob Chemother. 2011;66(5):1001–4. https://doi.org/10.1093/jac/dkr048.CrossRefPubMed

19.

Puzia W, Ronkiewicz P, Kuch A, Hryniewicz W, Sadowy E, Skoczyńska A. Streptococcus pneumoniae of serotype 19A before introduction of population based vaccination in Poland (P0359). In 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Amsterdam, 13–16 April 2019.

20.

Skoczynska A, Sadowy E, Bojarska K, et al. The current status of invasive pneumococcal disease in Poland. Vaccine. 2011;29(11):2199–205. https://doi.org/10.1016/j.vaccine.2010.09.100.CrossRefPubMed

21.

Facklam RR, Washington JA. Streptococcus and related catalase-negative gram-positive cocci. In: Balows A, Hausler WJ, Herrmann KL, Isenberg HD, Shadomy HJ, editors. Manual of clinical microbiology. Washington, DC: American Society for Microbiology; 1991. p. 238–57.

22.

Lawrence ER, Griffiths DB, Martin SA, George RC, Hall LM. Evaluation of semiautomated multiplex PCR assay for determination of Streptococcus pneumoniae serotypes and serogroups. J Clin Microbiol. 2003;41(2):601–7. https://doi.org/10.1128/JCM.41.2.601-607.2003.CrossRefPubMedPubMedCentral

23.

Pai R, Gertz RE, Beall B. Sequential multiplex PCR approach for determining capsular serotypes of Streptococcus pneumoniae isolates. J Clin Microbiol. 2006;44(1):124–31. https://doi.org/10.1128/JCM.44.1.124-131.2006.CrossRefPubMedPubMedCentral

24.

Neufeld F. Über die Agglutination der Pneumokokken und über die Theorie der Agglutination. Z Hyg Infektionskr. 1902;40:54–72.CrossRef

25.

EUCAST. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 12.0. 2022. http://www.eucast.org. Accessed 4 Apr 2023.

26.

Golden AR, Rosenthal M, Fultz B, et al. Characterization of MDR and XDR Streptococcus pneumoniae in Canada, 2007–13. J Antimicrob Chemother. 2015;70(8):2199–202. https://doi.org/10.1093/jac/dkv107.CrossRefPubMed

27.

Yamba Yamba L, Udden F, Fuursted K, Ahl J, Slotved HC, Riesbeck K. Extensive/multidrug-resistant pneumococci detected in clinical respiratory tract samples in Southern Sweden are closely related to international multidrug-resistant lineages. Front Cell Infect Microbiol. 2022;12: 824449. https://doi.org/10.3389/fcimb.2022.824449.CrossRefPubMedPubMedCentral

28.

Wilson K. Preparation of genomic DNA from bacteria. Curr Protoc Mol Biol. 2001. https://doi.org/10.1002/0471142727.mb0204s56. (Chapter 2: Unit 2 4).CrossRefPubMed

29.

Chen S, Zhou Y, Chen Y, Gu J. fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics. 2018;34(17):i884–90. https://doi.org/10.1093/bioinformatics/bty560.CrossRefPubMedPubMedCentral

30.

Prjibelski A, Antipov D, Meleshko D, Lapidus A, Korobeynikov A. Using SPAdes De Novo assembler. Curr Protoc Bioinform. 2020;70(1):e102. https://doi.org/10.1002/cpbi.102.CrossRef

31.

Jolley KA, Bray JE, Maiden MCJ. Open-access bacterial population genomics: BIGSdb software, the PubMLST.org website and their applications. Wellcome Open Res. 2018;3:124. https://doi.org/10.12688/wellcomeopenres.14826.1.CrossRefPubMedPubMedCentral

32.

Lees JA, Harris SR, Tonkin-Hill G, et al. Fast and flexible bacterial genomic epidemiology with PopPUNK. Genome Res. 2019;29(2):304–16. https://doi.org/10.1101/gr.241455.118.CrossRefPubMedPubMedCentral

33.

Brugger SD, Troxler LJ, Rufenacht S, et al. Polysaccharide capsule composition of pneumococcal serotype 19A subtypesi is unaltered among subtypes and independent of the nutritional environment. Infect Immun. 2016;84(11):3152–60. https://doi.org/10.1128/IAI.00474-16.CrossRefPubMedPubMedCentral

34.

Del Grosso M, Northwood JG, Farrell DJ, Pantosti A. The macrolide resistance genes erm(B) and mef(E) are carried by Tn2010 in dual-gene Streptococcus pneumoniae isolates belonging to clonal complex CC271. Antimicrob Agents Chemother. 2007;51(11):4184–6. https://doi.org/10.1128/AAC.00598-07.CrossRefPubMedPubMedCentral

35.

Hoskins J, Alborn WE Jr, Arnold J, et al. Genome of the bacterium Streptococcus pneumoniae strain R6. J Bacteriol. 2001;183(19):5709–17. https://doi.org/10.1128/JB.183.19.5709-5717.2001.CrossRefPubMedPubMedCentral

36.

Gamez G, Castro A, Gomez-Mejia A, et al. The variome of pneumococcal virulence factors and regulators. BMC Genomics. 2018;19(1):10. https://doi.org/10.1186/s12864-017-4376-0.CrossRefPubMedPubMedCentral

37.

Puzia W, Gawor J, Gromadka R, Skoczynska A, Sadowy E. Comparative genomic analysis of two ST320 Streptococcus pneumoniae isolates, representing serotypes 19A and 19F. BMC Genom Data. 2023;24(1):19. https://doi.org/10.1186/s12863-023-01118-5.CrossRefPubMedPubMedCentral

38.

Zapun A, Contreras-Martel C, Vernet T. Penicillin-binding proteins and beta-lactam resistance. FEMS Microbiol Rev. 2008;32(2):361–85. https://doi.org/10.1111/j.1574-6976.2007.00095.x.CrossRefPubMed

39.

Pan XS, Fisher LM. DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae. Antimicrob Agents Chemother. 1998;42(11):2810–6. https://doi.org/10.1128/AAC.42.11.2810.CrossRefPubMedPubMedCentral

40.

Kawamura-Sato K, Hasegawa T, Torii K, Ito H, Ohta M. Prevalence of Ile-460-Val/ParE substitution in clinical Streptococcus pneumoniae isolates that were less susceptible to fluoroquinolones. Curr Microbiol. 2005;51(1):27–30. https://doi.org/10.1007/s00284-005-4439-3.CrossRefPubMed

41.

Pikis A, Donkersloot JA, Rodriguez WJ, Keith JM. A conservative amino acid mutation in the chromosome-encoded dihydrofolate reductase confers trimethoprim resistance in Streptococcus pneumoniae. J Infect Dis. 1998;178(3):700–6. https://doi.org/10.1086/515371.CrossRefPubMed

42.

Haasum Y, Strom K, Wehelie R, et al. Amino acid repetitions in the dihydropteroate synthase of Streptococcus pneumoniae lead to sulfonamide resistance with limited effects on substrate K(m). Antimicrob Agents Chemother. 2001;45(3):805–9. https://doi.org/10.1128/AAC.45.3.805-809.2001.CrossRefPubMedPubMedCentral

43.

Muzzi A, Moschioni M, Covacci A, Rappuoli R, Donati C. Pilus operon evolution in Streptococcus pneumoniae is driven by positive selection and recombination. PLoS ONE. 2008;3(11): e3660. https://doi.org/10.1371/journal.pone.0003660.CrossRefPubMedPubMedCentral

44.

Bagnoli F, Moschioni M, Donati C, et al. A second pilus type in Streptococcus pneumoniae is prevalent in emerging serotypes and mediates adhesion to host cells. J Bacteriol. 2008;190(15):5480–92. https://doi.org/10.1128/JB.00384-08.CrossRefPubMedPubMedCentral

45.

Kaplan SL, Barson WJ, Lin PL, et al. Serotype 19A Is the most common serotype causing invasive pneumococcal infections in children. Pediatrics. 2010;125(3):429–36. https://doi.org/10.1542/peds.2008-1702.CrossRefPubMed

46.

Hanquet G, Kissling E, Fenoll A, et al. Pneumococcal serotypes in children in 4 European countries. Emerg Infect Dis. 2010;16(9):1428–39. https://doi.org/10.3201/eid1609.100102.CrossRefPubMedPubMedCentral

47.

Cho EY, Kang HM, Lee J, Kang JH, Choi EH, Lee HJ. Changes in serotype distribution and antibiotic resistance of nasopharyngeal isolates of Streptococcus pneumoniae from children in Korea, after optional use of the 7-valent conjugate vaccine. J Korean Med Sci. 2012;27(7):716–22. https://doi.org/10.3346/jkms.2012.27.7.716.CrossRefPubMedPubMedCentral

48.

Setchanova L, Alexandrova A, Pencheva D, et al. Rise of multidrug-resistant Streptococcus pneumoniae clones expressing non-vaccine serotypes among children following introduction of the 10-valent pneumococcal conjugate vaccine in Bulgaria. J Glob Antimicrob Resist. 2018;15:6–11. https://doi.org/10.1016/j.jgar.2018.05.012.CrossRefPubMed

49.

Tin Tin Htar M, Christopoulou D, Schmitt HJ. Pneumococcal serotype evolution in Western Europe. BMC Infect Dis. 2015;15:419. https://doi.org/10.1186/s12879-015-1147-x.CrossRefPubMedPubMedCentral

50.

Nakano S, Fujisawa T, Chang B, et al. Whole-genome analysis-based phylogeographic investigation of Streptococcus pneumoniae serotype 19A sequence type 320 isolates in Japan. Antimicrob Agents Chemother. 2022;66(2): e0139521. https://doi.org/10.1128/AAC.01395-21.CrossRefPubMed

51.

Ricketson LJ, Vanderkooi OG, Wood ML, Leal J, Kellner JD. Clinical features and outcomes of serotype 19A invasive pneumococcal disease in Calgary, Alberta. Can J Infect Dis Med Microbiol. 2014;25(2):e71–5. https://doi.org/10.1155/2014/196748.CrossRefPubMedPubMedCentral

52.

Moore MR, Gertz RE Jr, Woodbury RL, et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J Infect Dis. 2008;197(7):1016–27. https://doi.org/10.1086/528996.CrossRefPubMed

53.

Pai R, Moore MR, Pilishvili T, et al. Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States. J Infect Dis. 2005;192(11):1988–95. https://doi.org/10.1086/498043.CrossRefPubMed

54.

Deng X, Arya G, Memari N, et al. Genetic analysis of invasive pneumococcal isolates from children in Ontario, Canada, 2007–2012. Pediatr Infect Dis J. 2015;34(6):594–8. https://doi.org/10.1097/INF.0000000000000697.CrossRefPubMed

55.

Croucher NJ, Chewapreecha C, Hanage WP, et al. Evidence for soft selective sweeps in the evolution of pneumococcal multidrug resistance and vaccine escape. Genome Biol Evol. 2014;6(7):1589–602. https://doi.org/10.1093/gbe/evu120.CrossRefPubMedPubMedCentral

56.

Beall B, McEllistrem MC, Gertz RE Jr, et al. Pre- and postvaccination clonal compositions of invasive pneumococcal serotypes for isolates collected in the United States in 1999, 2001, and 2002. J Clin Microbiol. 2006;44(3):999–1017. https://doi.org/10.1128/JCM.44.3.999-1017.2006.CrossRefPubMedPubMedCentral

57.

Beall BW, Gertz RE, Hulkower RL, Whitney CG, Moore MR, Brueggemann AB. Shifting genetic structure of invasive serotype 19A pneumococci in the United States. J Infect Dis. 2011;203(10):1360–8. https://doi.org/10.1093/infdis/jir052.CrossRefPubMedPubMedCentral

58.

van der Linden M, Reinert RR, Kern WV, Imohl M. Epidemiology of serotype 19A isolates from invasive pneumococcal disease in German children. BMC Infect Dis. 2013;13:70. https://doi.org/10.1186/1471-2334-13-70.CrossRefPubMedPubMedCentral

59.

Corcoran M, Mereckiene J, Cotter S, et al. Using genomics to examine the persistence of Streptococcus pneumoniae serotype 19A in Ireland and the emergence of a sub-clade associated with vaccine failures. Vaccine. 2021;39(35):5064–73. https://doi.org/10.1016/j.vaccine.2021.06.017.CrossRefPubMed

60.

Croucher NJ, Hanage WP, Harris SR, et al. Variable recombination dynamics during the emergence, transmission and “disarming” of a multidrug-resistant pneumococcal clone. BMC Biol. 2014;12:49. https://doi.org/10.1186/1741-7007-12-49.CrossRefPubMedPubMedCentral

61.

Croucher NJ, Harris SR, Fraser C, et al. Rapid pneumococcal evolution in response to clinical interventions. Science. 2011;331(6016):430–4. https://doi.org/10.1126/science.1198545.CrossRefPubMedPubMedCentral

62.

De Angelis G, Moschioni M, Muzzi A, et al. The Streptococcus pneumoniae pilus-1 displays a biphasic expression pattern. PLoS ONE. 2011;6(6): e21269. https://doi.org/10.1371/journal.pone.0021269.CrossRefPubMedPubMedCentral

63.

Barocchi MA, Ries J, Zogaj X, et al. A pneumococcal pilus influences virulence and host inflammatory responses. Proc Natl Acad Sci U S A. 2006;103(8):2857–62. https://doi.org/10.1073/pnas.0511017103.CrossRefPubMedPubMedCentral

64.

Dzaraly ND, Muthanna A, Mohd Desa MN, et al. Pilus islets and the clonal spread of piliated Streptococcus pneumoniae: a review. Int J Med Microbiol. 2020;310(7):151449. https://doi.org/10.1016/j.ijmm.2020.151449.CrossRefPubMed

65.

Gianfaldoni C, Censini S, Hilleringmann M, et al. Streptococcus pneumoniae pilus subunits protect mice against lethal challenge. Infect Immun. 2007;75(2):1059–62. https://doi.org/10.1128/IAI.01400-06.CrossRefPubMed

66.

Skoczynska A, Kuch A, Sadowy E, et al. Recent trends in epidemiology of invasive pneumococcal disease in Poland. Eur J Clin Microbiol Infect Dis. 2015;34(4):779–87. https://doi.org/10.1007/s10096-014-2283-8.CrossRefPubMed

67.

Holmes AH, Moore LS, Sundsfjord A, et al. Understanding the mechanisms and drivers of antimicrobial resistance. Lancet. 2016;387(10014):176–87. https://doi.org/10.1016/S0140-6736(15)00473-0.CrossRefPubMed

68.

Olczak-Pienkowska A, Skoczynska A, Hryniewicz W. Monthly trends in antimicrobial consumption and influenza incidence at the community level in 2014 in Poland. Pol Arch Intern Med. 2018;128(12):731–8. https://doi.org/10.20452/pamw.4368.CrossRefPubMed

69.

Camilli R, Pettini E, Grosso MD, Pozzi G, Pantosti A, Oggioni MR. Zinc metalloproteinase genes in clinical isolates of Streptococcus pneumoniae: association of the full array with a clonal cluster comprising serotypes 8 and 11A. Microbiology (Reading). 2006;152(Pt 2):313–21. https://doi.org/10.1099/mic.0.28417-0.CrossRefPubMed

Title: Highly Resistant Serotype 19A Streptococcus pneumoniae of the GPSC1/CC320 Clone from Invasive Infections in Poland Prior to Antipneumococcal Vaccination of Children
Authors: Weronika Puzia
Jan Gawor
Robert Gromadka
Karolina Żuchniewicz
Izabela Wróbel-Pawelczyk
Patrycja Ronkiewicz
Agnieszka Gołębiewska
Waleria Hryniewicz
Ewa Sadowy
Anna Skoczyńska
Publication date: 13-07-2023
Publisher: Springer Healthcare
Keywords: Pneumococcus
Vaccination
Antibiotic
Published in: Infectious Diseases and Therapy / Issue 8/2023
Print ISSN: 2193-8229
Electronic ISSN: 2193-6382
DOI: https://doi.org/10.1007/s40121-023-00842-w

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 8/2023

Cefiderocol Versus Colistin for the Treatment of Carbapenem-Resistant Acinetobacter baumannii Complex Bloodstream Infections: A Retrospective, Propensity-Score Adjusted, Monocentric Cohort Study

Applying Rituximab During the Conditioning Regimen Prevents Epstein–Barr Virus Infection Following Allogeneic Hematopoietic Stem Cell Transplant in a Children’s Cohort: A Retrospective Case–Control Study

Combination Therapy of Ceftazidime/Avibactam for the Treatment of Patients Infected with Carbapenem-Resistant Klebsiella pneumoniae: A Multicenter Retrospective Study

Assessment of Drug–Drug Interaction Risk Between Intravenous Fentanyl and the Glecaprevir/Pibrentasvir Combination Regimen in Hepatitis C Patients Using Physiologically Based Pharmacokinetic Modeling and Simulations

Safety and Clinical Benefits of Adacel® and Adacel®-Polio Vaccination in Pregnancy: A Structured Literature Review

Comparison of Risk Stratification Approaches to Identify Patients with Clostridioides difficile Infection at Risk for Multidrug-Resistant Organism Gut Microbiota Colonization

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials